Linagliptine Zentiva (Linagliptin)

Linagliptin works by selectively inhibiting the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin secretion, reduces glucagon release, and slows gastric emptying, collectively lowering blood glucose concentrations.

The specific dose of Linagliptine Zentiva is determined by the prescribing clinician based on the individual’s clinical condition, renal and hepatic function, and concomitant therapies. The prescriber will select the appropriate strength and dosing schedule according to current treatment guidelines.

Safety of Linagliptine Zentiva in pregnancy and lactation has not been established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Linagliptine Zentiva. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptine Zentiva shares the same class mechanism as other DPP‑4 inhibitors but is distinguished by its high binding affinity and minimal renal excretion, which means dose adjustment is generally not required in patients with renal impairment. Efficacy and safety profiles are comparable, though individual tolerability may vary.

Linagliptine Zentiva should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight and excessive heat to maintain product stability throughout its shelf life.

The medication is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing instructions provided by their prescriber, who may adjust timing based on other concurrent medications.

Serious adverse events, although rare, include pancreatitis, severe allergic reactions such as anaphylaxis, and bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, signs of an allergic reaction, or unexplained skin eruptions.

Linagliptine Zentiva is contraindicated in individuals with a known hypersensitivity to linagliptin or any of the tablet’s excipients. Caution is also advised for patients with a history of pancreatitis, severe hepatic impairment, or those taking concomitant medications that may cause dangerous hypoglycaemia.